Jan Stahlberg has bought DMAC on 4 days since Jun 2024

Jan Stahlberg is a prominent investor and the 10% Owner of DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biopharmaceutical company focused on treatments for acute ischemic stroke and cardio-renal disease.( He beneficially owns over 8.8 million shares through his role as board member and sole owner of Trill AB, a Swedish entity that directly holds the shares, granting him sole voting and dispositive power.(

Stahlberg has demonstrated strong confidence in DMAC through substantial recent acquisitions, including 240,352 shares on November 19, 2025, at $7.21 per share (totaling ~$1.73 million), additional purchases totaling over 1 million shares in late 2025 valued at approximately $7.6 million, and earlier buys such as 293,601 shares in August 2025.( These transactions increased his stake to about 8,825,742 shares, valued at over $73 million as of late 2025.(

Written by Perplexity from public sources.